Physician profile
Stephen D Tedder
NPI 1093711186
$1,857.81
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $679 · 2020: $271 · 2021: $432 · 2022: $212 · 2023: $126 · 2024: $137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $263.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $263.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $499.59 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $317.74 | 2019-2021 | |
| Allergan, INC. | $141.44 | 2020-2021 | |
| Sun Pharmaceutical Industries INC. | $138.68 | 2019-2022 | |
| Amgen INC. | $136.91 | 2024 | Tepezza |
| Mallinckrodt Hospital Products INC. | $126.42 | 2023 | Acthar |
| Oyster Point Pharma, INC. | $125.00 | 2022 | |
| Novartis Pharmaceuticals Corporation | $103.28 | 2019-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $68.27 | 2019 | |
| Alcon Vision LLC | $53.57 | 2019-2022 | |
| Kala Pharmaceuticals, INC. | $46.04 | 2019-2020 | |
| Omeros Corporation | $32.93 | 2019 | |
| Shire North American Group INC | $19.18 | 2019 | |
| Akorn Operating Company LLC | $18.54 | 2021 | |
| Akorn, INC. | $15.41 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $14.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Tedder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.